Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 20/20 | 0.81 |
| ▸ | HSP90AA1 | P07900 | 18/20 | 0.81 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.78 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL500866 | 0.91 | HSP90AB1 (0.81) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL9924656 | 0.91 | HSP90AB1 (0.81) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL4566979 | 0.90 | HSP90AB1 (0.79) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL419884 | 0.90 | HSP90AB1 (1.00) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL29357308 | 0.90 | HSP90AB1 (1.00) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL25602993 | 0.89 | HSP90AB1 (0.77) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| Ganetespib SCHEMBL419750 | 0.88 | HSP90AB1 (1.00) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| Ganetespib SCHEMBL29352120 | 0.88 | HSP90AB1 (1.00) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| Ganetespib SCHEMBL29376128 | 0.88 | HSP90AB1 (1.00) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL15042948 | 0.88 | HSP90AB1 (0.76) | HSP90AB1HSP90AA1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221345-A1 | COMBINATION THERAPY OF HSP90 INHIBITORS WITH PLATINUM-CONTAINING AGENTS | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20170340652-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. | 2017-11-30 | — | — | US | disclosed |
| US-9439899-B2 | Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors | SYNTA PHARMACEUTICALS CORP. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9402831-B2 | Combination therapy of HSP90 inhibitors with BRAF inhibitors | SYNTA PHARMACEUTICAL CORP. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160120849-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR | SYNTA PHARMACEUTICALS CORP (US) | 2016-05-05 | — | — | US | disclosed |
| US-20150366885-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2015-12-24 | — | — | US | disclosed |
| US-9205086-B2 | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor | SYNTA PHARMACEUTICALS CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9120745-B2 | Triazole compounds that modualte HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150150850-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150099721-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-04-09 | — | — | US | disclosed |
| US-20140228418-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH MEK INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140194388-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8742133-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20140051664-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH RADIOTHERAPY | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051665-A1 | PROSTATE CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140045908-A1 | HSP90 INHIBITORY COMPOUNDS IN TREATING JAK/STAT SIGNALING-MEDIATED CANCERS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130150385-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20120245186-A1 | COMBINATION CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120064175-A1 | HSP90 Inhibitors for Treating Non-Small Cell Lung Cancer in Wild-Type EGFR and/or KRAS Patients | SYNTA PHARMACEUTICALS CORP. | 2012-03-15 | — | — | US | disclosed |
| US-20110195094-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221345-A1 | COMBINATION THERAPY OF HSP90 INHIBITORS WITH PLATINUM-CONTAINING AGENTS | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AB1 1/4885HSP90AA1 2/4885HSP90B1 3/4885 |
| US-20160120849-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR | EGFR, HSP90AB1, HSP90AA1 | HSP90AB1 2/4885HSP90AA1 3/4885HSP90B1 4/4885 |
| US-20140045908-A1 | HSP90 INHIBITORY COMPOUNDS IN TREATING JAK/STAT SIGNALING-MEDIATED CANCERS | JAK2, STAT3, HSP90AB1 | HSP90AB1 3/4885HSP90AA1 4/4885HSP90B1 8/4885 |
| US-20120245186-A1 | COMBINATION CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AB1 1/4885HSP90AA1 3/4885HSP90B1 2/4885 |
| US-20150099721-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | ROS1, RET, HSP90AB1 | HSP90AB1 3/4885HSP90AA1 4/4885HSP90B1 7/4885 |
| US-20110195094-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AB1 1/4885HSP90AA1 3/4885HSP90B1 2/4885 |
| US-20170340652-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AB1 1/4885HSP90AA1 2/4885HSP90B1 3/4885 |
| US-20140051664-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH RADIOTHERAPY | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AB1 1/4885HSP90AA1 2/4885HSP90B1 3/4885 |
| US-20140194388-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AB1 1/4885HSP90AA1 2/4885HSP90B1 3/4885 |
| US-20130150385-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR | EGFR, HSP90AB1, HSP90B1 | HSP90AB1 2/4885HSP90AA1 4/4885HSP90B1 3/4885 |
| US-20150150850-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | HSP90AB1, MET, HSP90AA1 | HSP90AB1 1/4885HSP90AA1 3/4885HSP90B1 5/4885 |
| US-20140051665-A1 | PROSTATE CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AB1 1/4885HSP90AA1 2/4885HSP90B1 3/4885 |
| US-20150366885-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AB1 1/4885HSP90AA1 3/4885HSP90B1 2/4885 |
| US-20140228418-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH MEK INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AB1 1/4885HSP90AA1 2/4885HSP90B1 3/4885 |
| US-20120064175-A1 | HSP90 Inhibitors for Treating Non-Small Cell Lung Cancer in Wild-Type EGFR and/or KRAS Patients | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AB1 1/4885HSP90AA1 2/4885HSP90B1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.